TheStreet Upgrades Vanda Pharmaceuticals (VNDA) to “B-“

Share on StockTwits

TheStreet upgraded shares of Vanda Pharmaceuticals (NASDAQ:VNDA) from a c rating to a b- rating in a research report released on Friday morning.

Several other equities research analysts have also weighed in on VNDA. Oppenheimer set a $27.00 price objective on Vanda Pharmaceuticals and gave the stock a buy rating in a research note on Thursday, August 2nd. Cantor Fitzgerald reissued a hold rating and set a $26.00 price objective on shares of Vanda Pharmaceuticals in a research note on Wednesday, October 3rd. Zacks Investment Research raised Vanda Pharmaceuticals from a hold rating to a buy rating and set a $26.00 price objective for the company in a research note on Friday, October 12th. Seaport Global Securities reissued a buy rating and set a $26.00 price objective on shares of Vanda Pharmaceuticals in a research note on Thursday, August 2nd. Finally, Citigroup raised their price objective on Vanda Pharmaceuticals from $27.00 to $31.00 and gave the stock a buy rating in a research note on Tuesday, October 16th. One analyst has rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has an average rating of Buy and a consensus target price of $26.86.

VNDA opened at $20.07 on Friday. The firm has a market cap of $1.07 billion, a PE ratio of -57.34 and a beta of 0.52. Vanda Pharmaceuticals has a fifty-two week low of $11.90 and a fifty-two week high of $23.50.

Vanda Pharmaceuticals (NASDAQ:VNDA) last released its quarterly earnings data on Wednesday, August 1st. The biopharmaceutical company reported $0.09 earnings per share for the quarter, topping the consensus estimate of ($0.05) by $0.14. The business had revenue of $47.40 million during the quarter, compared to analyst estimates of $47.28 million. Vanda Pharmaceuticals had a return on equity of 0.68% and a net margin of 0.73%. The company’s revenue was up 12.6% compared to the same quarter last year. During the same period last year, the company posted $0.03 EPS. On average, research analysts anticipate that Vanda Pharmaceuticals will post -0.02 earnings per share for the current year.

Institutional investors have recently modified their holdings of the company. Trexquant Investment LP acquired a new stake in shares of Vanda Pharmaceuticals in the second quarter worth $212,000. Hartford Investment Management Co. acquired a new stake in shares of Vanda Pharmaceuticals in the second quarter worth $214,000. NumerixS Investment Technologies Inc boosted its position in shares of Vanda Pharmaceuticals by 92.9% in the second quarter. NumerixS Investment Technologies Inc now owns 11,835 shares of the biopharmaceutical company’s stock worth $227,000 after buying an additional 5,700 shares during the period. Xact Kapitalforvaltning AB acquired a new stake in shares of Vanda Pharmaceuticals in the second quarter worth $240,000. Finally, Dynamic Technology Lab Private Ltd acquired a new stake in shares of Vanda Pharmaceuticals in the first quarter worth $242,000. 93.54% of the stock is owned by institutional investors and hedge funds.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system disorders. The company's marketed products include HETLIOZ (tasimelteon), a product for the treatment of non-24-hour sleep-wake disorders; and Fanapt (iloperidone), a product for the treatment of schizophrenia.

Featured Article: Investing in Growth Stocks

Analyst Recommendations for Vanda Pharmaceuticals (NASDAQ:VNDA)

Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply